Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
Business Wire•26/10/2026•07:00 ET
0
Key Highlights
- ➤18 ASN Kidney Week abstracts, including three oral presentations, support Natera’s Renasight CKD genetic testing
- ➤CKD diagnosis took 5.3 years after abnormal indicators; median eGFR fell from 75 to 66
- ➤Only one-third of KDIGO-aligned high-risk patients had documented nephrology care
- ➤High-risk hereditary or structural kidney disease patients had just 26.6% documented nephrology care
- ➤Nephrology referrals took a median 149 days among high-risk patients receiving care
Expert Statements
Sangeeta Bhorade, Chief Medical Officer, Organ Health, Natera
“These findings underscore the need for earlier etiologic evaluation. Renasight genetic testing is designed to address this need by clarifying the cause of kidney disease and supporting earlier, more targeted specialist referrals”
Sangeeta Bhorade, Chief Medical Officer, Organ Health, Natera
“Renasight is an essential tool in CKD management, which we believe should be a standard part of care for patients with signs of the disease.”
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
Analyses drawn from a large real-world database of patients underscore how genetic testing can support better care in chronic kidney disease (CKD)
Get started
Create a free account to read the full story.